News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Notice of Cipher Pharmaceuticals (DND.TO) Fiscal 2011 Third Quarter Conference Call


10/19/2011 1:20:42 PM

MISSISSAUGA, ON, Oct. 19, 2011 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a conference call on Wednesday, October 26, 2011 at 8:30 a.m. (ET) to discuss its fiscal 2011 third quarter financial results. Cipher invites all interested parties to participate. You can join the call by dialing 647-427-7450 or 1-888-231-8191. Please call in 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins.

Larry Andrews, President and CEO, will chair the call. A question and answer session will follow, at which time the operator will direct participants as to the correct procedure for submitting questions. A taped replay of the conference call will be available until Wednesday, November 2, 2011 by calling 416-849-0833 or 1-855-859-2056, reference number 20101236. A live audio webcast of the conference call will be available through www.cipherpharma.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. An archived replay of the webcast will be available for 365 days.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners. The Company's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip™ and will be marketed in Canada as Durela™. The Company's third product, a novel formulation of the acne treatment isotretinoin, recently completed its final Phase III safety study, with regulatory submissions planned in the United States and Canada in Q4, 2011.

Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding.

For more information, please visit www.cipherpharma.com

For further information:

Craig Armitage

Investor Relations

The Equicom Group

(416) 815-0700 ext 278

(416) 815-0080 fax

carmitage@equicomgroup.com

Larry Andrews

President and CEO

Cipher Pharmaceuticals

(905) 602-5840 ext 324

(905) 602-0628 fax

landrews@cipherpharma.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES